RSS Feeds
Cis-diamminedichloroplatinum (II)
A New Anticancer Drug
- MARCEL ROZENCWEIG, M.D.;
- DANIEL D. VON HOFF, M.D.;
- MILAN SLAVIK, M.D., Ph.D.; and
- FRANCO M. MUGGIA, M.D., F.A.C.P.
Abstract
Cis-diamminedichloroplatinum (II) (DDP) leads the series of platinum coordination complexes, a new class of cytotoxic agents. The antitumor and toxic effects of this drug are discussed. It has displayed encouraging results in testicular tumors. The drug's therapeutic effectiveness has also been recognized in a variety of other solid tumors, particularly ovarian, bladder, and head and neck malignancies. Gastrointestinal, renal, audiologic, and relatively minor hematologic toxicities may be encountered, but promising methods have been developed to increase the therapeutic index of DDP.
Article and Author Information
-
▸From the Cancer Therapy Evaluation Program, National Cancer Institute, National Institutes of Health; Bethesda, Maryland.
-
▸Requests for reprints should be addressed to Marcel Rozencweig, M.D.; NIH-NCI Building 37, Room 6E12; Bethesda, MD 20014.
-
- Received August 30, 1976.
- Accepted January 20, 1977.
Related Clinical Content
